Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.
Analyst Ratings For Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However, the news failed to move markets.
10 Biggest Price Target Changes For Wednesday
Morgan Stanley boosted the price target on Adobe Inc. (NASDAQ: ADBE) from $610 to $736. Adobe shares rose 0.2% to $646.33 in pre-market trading.
After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19.
U.S. Govt Calls For Additional Doses Of Regeneron’s COVID-19 Antibody Therapy
The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 antibody cocktail. Read Next: FDA Expands EUA for…
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)
HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $831
HC Wainwright & Co. analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $787 to $831.
Regeneron Announced New U.S. Government Agreement to Purchase 1.4M Additional Doses of REGEN-COV Antibody Cocktail @$2,100/Dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab). The government will continue to provide REGEN-COV at no cost to patients.
Analyst Ratings For Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: